Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Hypertension, Cardiovascular Diseases, C...
Phase NA
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This study is a mechanistic clinical trial designed to investigate the effects of the circadian system and sleep on non-dipping blood pressure (BP) in people with hypertension (HTN).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: At-home Polysomnography — Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
  • Other: Circadian Protocol — Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
  • Other: Rested Wakefulness Trial — Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
  • Other: Overnight Sleep Trial — Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
  • Behavioral: Regularized Sleep Schedule — All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.

Primary Outcomes

  • Sleep duration (At-home Polysomnography) (1-2 nights)
  • Sleep Episodes (At-home Polysomnography) (1-2 nights)
  • Blood pressure (Circadian and Overnight sleep vs. rested wakefulness trial) (7 days)
  • Heart rate (Circadian and Overnight sleep vs. rested wakefulness trial) (7 days)
  • Heart rate variability (Circadian and Overnight sleep vs. rested wakefulness trial) (7 days)
  • Epinephrine (Circadian and Overnight sleep vs. rested wakefulness trial) (7 days)
  • Norepinephrine (Circadian and Overnight sleep vs. rested wakefulness trial) (7 days)
  • Aldosterone (Circadian and Overnight sleep vs. rested wakefulness trial) (7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-04
Completion: 2029-03-30
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oregon Health and Science University
Principal Investigators:
  • Saurabh S Thosar, PhD (PRINCIPAL_INVESTIGATOR) - Oregon Health and Science University
Contact Information
Study Contact:
Nicole Chaudhary, MPH
5034945536
clinphys@ohsu.edu
Saurabh S Thosar, PhD
503-494-2064
clinphys@ohsu.edu
Oregon Health and Science University
Saurabh S Thosar, PhD
Oregon Health and Science University
Interventions
  • Other: At-home Polysomnography — Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
  • Other: Circadian Protocol — Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
  • Other: Rested Wakefulness Trial — Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
  • Other: Overnight Sleep Trial — Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
  • Behavioral: Regularized Sleep Schedule — All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
Study Locations (1 sites)
Oregon Health and Science University, Portland, Oregon 97239 United States
Eligibility Criteria
Inclusion Criteria: * Ages 25-64 * BMI 18.5-42kg/m2 * Hypertension (average resting blood pressure between 130/80 mmHg and 160/100 mmHg) Exclusion Criteria: * Over 5 pack-years of smoking; * Prior shift work within 12 months prior to the study; * Travel greater than three time zones for at least 3 months; * History of heart failure, cardiomyopathy, or history of bypass surgery, angioplasty, or previous myocardial infarction; * Acute or chronic diseases (except hypertension) that may affect outcome measures; * History of psychological conditions; * Sleep disorders, like severe sleep apnea, insomnia, etc.; * Prescription medications (Contraceptives and anti-hypertensive medications are permissible); * History of Illicit drug use and alcohol dependency; * 30 days free of cannabis use prior to the study; * Pregnancy; * Upper cut-off of 160/100 mmHg for BP
Conditions Congenital Diaphragmatic Hernia, Pulmona...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Fetal Tracheal Occlusion — Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of \<25%, LHR \<1, o/e LHR\<30% (moderate), singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days, no maternal disease, maternal age \> 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center.

Primary Outcomes

  • Change lung growth on prenatal imaging (prenatal period up to 40 weeks gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2016-11
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Principal Investigators:
  • Kurt Schibler, MD (STUDY_CHAIR) - CCHMC Oversight Data Safety Monitoring Committee
Contact Information
Study Contact:
Foong-Yen Lim, MD
(513) 636-6259
Foong-Yen.Lim@cchmc.org
Jose Peiro, MD, PhD
(513) 803-4563
Jose.Peiro@cchmc.org
Foong-Yen Lim, MD
513-803-5270
Foong.Yen.Lim@cchmc.org
Cincinnati Children's Hospital Medical Center (CCHMC)
Interventions
  • Device: Fetal Tracheal Occlusion — Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of \<25%, LHR \<1, o/e LHR\<30% (moderate), singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days, no maternal disease, maternal age \> 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center.
Study Locations (1 sites)
Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio 45229 United States
Eligibility Criteria
Inclusion Criteria: * Isolated CDH with liver up * Severe pulmonary hypoplasia with ultrasound O/E LHR \<25% at the time of surgery * Gestational age at FETO procedure 27 weeks 0 days to 29 weeks 6 days * Moderate pulmonary hypoplasia with ultrasound O/E LHR \<30% and liver-up at the time of surgery * Gestational age at FETO procedure 30 weeks 0 days to 31 weeks 6 days in this moderate category * Maternal age greater than or equal to 18 years * Gestational age at enrollment prior to 29 weeks 6 days, or 31 weeks 6 days in moderate category * Normal karyotype or FISH * Normal fetal echocardiogram * Singleton pregnancy * Willing to remain in the greater Cincinnati area for remainder of pregnancy * Family considered and decline option of termination of the pregnancy at less than 24 weeks 0 days * Family meets psychosocial criteria Exclusion Criteria: * Patient \< 18 years old * Multi-fetal pregnancy * Rubber latex allergy * Preterm labor, cervix shortened (\<15 mm) or uterine anomaly strongly predisposing to preterm labor, placenta previa * Bilateral CDH, isolated left sided CDH with an O/E \> 30% * Additional fetal anomaly by ultrasound, MRI, or echocardiogram * Chromosomal abnormalities * Maternal contraindications to fetoscopic surgery or severe maternal condition in pregnancy * Incompetent cervix with or without a cerclage * Placental abnormalities known at time of enrollment * Maternal HIV, Hepatits B, Hepatitis C * Maternal uterine anomaly * No safe or technically feasible fetoscopic approach to balloon placement * Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy
Conditions Pulmonary Hypertension Associated With H...
Phase PHASE3
Enrollment 540
Locations 141 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: TNX-103 — Oral levosimendan
  • Drug: Placebo — Matching placebo (oral)

Primary Outcomes

  • 6-Minute Walk Distance (6MWD) (26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-03-03
Completion: 2029-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tenax Therapeutics, Inc.
Contact Information
Study Contact:
Akshata Ashokkumar
(919) 855-2118
a.ashokkumar@tenaxthera.com
Katelyn Jansson
(919) 855-2119
k.jansson@tenaxthera.com
Interventions
  • Drug: TNX-103 — Oral levosimendan
  • Drug: Placebo — Matching placebo (oral)
Study Locations (141 sites)
Tenax Investigational Site, Alexander City, Alabama 35010 United States
Tenax Investigational Site, Tucson, Arizona 85724 United States
Tenax Investigational Site, Sacramento, California 95816 United States
Tenax Investigational Site, San Francisco, California 94143 United States
Tenax Investigational Site, Stanford, California 94305-5208 United States
Tenax Investigational Site, Torrance, California 90502 United States
Tenax Investigational Site, Athens, Georgia 30606 United States
Tenax Investigational Site, Atlanta, Georgia 30322 United States
Tenax Investigational Site, Chicago, Illinois 60611-4494 United States
Tenax Investigational Site, Chicago, Illinois 60637 United States
Eligibility Criteria
Inclusion Criteria: 1. Men or women, ≥18 to 85 years of age 2. NYHA Class II or III or ambulatory NYHA Class IV symptoms 3. A diagnosis of World Health Organization (WHO) Group 2 PH-HFpEF with qualifying hemodynamics verified by right heart catheterization (RHC) 4. A qualifying baseline RHC 5. A qualifying echocardiogram 6. A qualifying 6-MWD 7. A 48-hour ambulatory cardiac rhythm monitor during the Screening Period 8. Requirements related to child bearing potential, contraception, and egg/sperm donation) Exclusion Criteria: 1. A diagnosis of PH WHO Groups 1, 3, 4, or 5 2. Echocardiographic evidence for hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy 3. Structural heart repair or replacement of the aortic valve or mitral valve (surgical or percutaneous) OR, planned valve intervention OR, the presence of significant valve disease 4. A diagnosis of pre-existing lung disease 5. History of severe allergic or anaphylactic reaction or hypersensitivity to the excipients in the investigational product 6. Major surgery within 60 days 7. Prior heart, lung, or heart-lung transplants or life expectancy of \<12 months 8. History of clinically significant other diseases that may limit or complicate participation in the study
Conditions Pigmentary Glaucoma
Phase Not Applicable
Enrollment 11
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.

Design

Study type: Observational Observational model: Other Time perspective: Retrospective

Interventions / Regimen

  • Procedure: Ab-interno 120° Trabeculotomy — A minimally invasive glaucoma surgery (MIGS) procedure performed via an ab interno approach, involving a 120-degree incision of the trabecular meshwork to improve aqueous humor outflow.

Primary Outcomes

  • Change in Intraocular Pressure (IOP) at 6 Months Postoperatively (6 months postoperatively)
  • Change in the Number of Intraocular Pressure-Lowering Medications at 6 Months (6 months postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-01
Completion: 2026-09-30
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: false
Enrollment: 11 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhongnan Hospital
Principal Investigators:
  • Wen Zeng, doctor (PRINCIPAL_INVESTIGATOR) - Zhongnan Hospital
  • Nan Zhang, doctor (PRINCIPAL_INVESTIGATOR) - Zhongnan Hospital
  • Xuetian Yu (PRINCIPAL_INVESTIGATOR) - The Second Clinical College of Wuhan University
Contact Information
Study Contact:
Min Ke, doctor
18672395959
Keminyk@163.com
Xiaomin Chen, doctor
13657237773
xminchen@whu.edu.cn
Min Ke, Doctor
+86-18672395959
keminyk@163.com
Zhongnan Hospital of Wuhan University
Interventions
  • Procedure: Ab-interno 120° Trabeculotomy — A minimally invasive glaucoma surgery (MIGS) procedure performed via an ab interno approach, involving a 120-degree incision of the trabecular meshwork to improve aqueous humor outflow.
Study Locations (1 sites)
Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071 China
Eligibility Criteria
Inclusion Criteria: * Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects; * Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment; * Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements; * Able to complete regular follow-up for at least 6 months postoperatively. Exclusion Criteria: * Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma; * Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment; * Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation; * Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up; * Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.
Conditions Medication Adherence, Medication Safety,...
Phase NA
Enrollment 640
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Medication management services (MMS) is a pharmacist-led service of optimizing the medication use and health outcomes, by promoting medication safety and enhancing the ability in self-management of health and diseases of patients and their caregivers. Yet, only limited evidence on the implementation of MMS service in Hong Kong is available. The goal of this clinical trial is to evaluate the cost effectiveness and effects of implementing MMS in community pharmacies owned by 8 non-government organizations (NGOs) in Hong Kong on humanistic and clinical outcomes in patients with hypertension and/or type II diabetes mellitus. The clinical trial aims to look into the following aspects: * To evaluate the perception and satisfaction of patients on MMS service * To investigate whether MMS could improve patients' adherence to their medication regimen, health-related quality of life, health outcomes and health service utilization, as well as their ability to understand and cope with their illness and drug-related problems * To identify and categorize the types of drug-related problems identified during MMS * To evaluate the cost-effectiveness of implementing MMS in community pharmacies MMS services will be rolled out in a total of 8 NGO community pharmacies progressively (2 pharmacies per phase) in 4 successive phases. Participants will complete the questionnaires at the following time points throughout the trial, namely 1) during recruitment, 2) baseline (1 month before MMS), 3) 3 months after MMS begins, 4) 12 months after MMS begins, and 5) 24 months after MMS begins. Researchers will compare the results of questionnaires conducted at different time points to identify the potential changes in the effects of MMS. Furthermore, researchers will link up the electronic health records of the participants and identify the potential changes in the health outcomes and health service utilizations after receiving MMS.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Medication Management Service (MMS) — Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.

Primary Outcomes

  • Medication adherence (Medication adherence will be assessed at 5 time points, namely 1) during recruitment, 2) baseline (1 month before MMS), 3) 3 months after MMS begins, 4) 12 months after MMS begins, and 5) 24 months after MMS begins.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-06
Completion: 2027-05-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 640 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: The Hong Kong Jockey Club Charities Trust, Hong Kong Sheng Kung Hui Welfare Council Limited, Hong Kong Young Women's Christian Association, Haven of Hope Hospital, Pok Oi Hospital, St. James' Settlement, Aberdeen Kai-fong Welfare Association, Health In Action, Lok Sin Tong Benevolent Society, Kowloon
Contact Information
Study Contact:
Ian Chi Kei Wong, PhD
+852 3917 9441
wongick@hku.hk
Eric Yuk Fai Wan, PhD
+852 2831 5057
yfwan@hku.hk
Kam Kit Mak
3550 5460
kennethmak.kk@aka.org.hk
Aberdeen Kai-Fong Welfare Association A-Lively Community Pharmacy
Interventions
  • Behavioral: Medication Management Service (MMS) — Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
Study Locations (8 sites)
Aberdeen Kai-Fong Welfare Association A-Lively Community Pharmacy, Hong Kong, Hong Kong
Health In Action Community Pharmacy, Hong Kong, Hong Kong
Hong Kong Sheng Kung Hui Welfare Council Community Pharmacy, Hong Kong, Hong Kong
PHARM+ Haven of Hope Community Pharmacy, Hong Kong, Hong Kong
PHARM+ Pok Oi Hospital Community Pharmacy, Hong Kong, Hong Kong
PHARM+ St. James' Settlement Community Pharmacy, Hong Kong, Hong Kong
PHARM+ The Lok Sin Tong Community Pharmacy, Hong Kong, Hong Kong
PHARM+ YWCA Community Pharmacy, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * aged 18 years or above * diagnosed with Type 2 diabetes mellitus and/or hypertension * having regular follow-up on Type 2 diabetes mellitus and/or hypertension at Hospital Authority * no A\&E admission/hospitalization in the past 3 months * no recent changes in medication regimen in the past 3 months * polypharmacy (taking 5 or more chronic medications) * using at least 1 high-risk medication (Anticoagulants, Oral hypoglycaemics, Insulins, psychotropic medications or immunosuppressants) * able to communicate in Cantonese and/or English Exclusion Criteria: * aged below 18 * unable to give informed consent * unable to communicate in Cantonese and/or English
Conditions Glaucoma, Open-Angle, Cataract Complicat...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are: * Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled POAG. * Whether the PEI+GT has value of health economics. Participants will be randomized to receive either PEI+GT or PEI+MED, and followed up with a 1-year period as a primary outcome.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: PEI+GT — After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
  • Procedure: PEI+MED — Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.

Primary Outcomes

  • IOP at 12 months after surgery. (Postopertive 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-28
Completion: 2029-12-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Collaborators: West China Hospital, Chongqing Medical University, The Second Hospital of Anhui Medical University, Handan City Eye Hospital, Shijiazhuang People's Hospital, Chengdu First People's Hospital, Guangdong Hospital of Traditional Chinese Medicine, Zhuhai, Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Huizhou Municipal Central Hospital
Contact Information
Study Contact:
Xiulan Zhang, MD. PhD
+86 13570166308
zhangxl2@mail.sysu.edu.cn
Yunhe Song, MD, PhD
+86 13059106657
songyh33@mail.sysu.edu.cn
Xiulan Zhang, MD, PhD
+86 13059106657
zhangxl2@mail.sysu.edu.cn
Zhongshan Ophthalmic Center, Sun Yat-sen University
Interventions
  • Procedure: PEI+GT — After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
  • Procedure: PEI+MED — Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
Study Locations (1 sites)
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060 China
Eligibility Criteria
Inclusion Criteria: 1. 40 ≤ Age ≤ 85 years, gender unrestricted. 2. Diagnosed with POAG. 3. Controlled IOP under 1 to 4 topical hypotensive medications, IOP ≤ 24 mmHg 4. Mean deviation (MD) for perimetry ≥ -16dB. 5. Presence of clinically significant cataract and best-corrected visual acuity measured using the ETDRS chart ≤ 0.63. 6. Voluntary participation of the patient in this study, signing an informed consent form, and agreeing to follow-up visits according to the study protocol. Exclusion Criteria: 1. Any history of intraocular surgery or ocular trauma. 2. Presence of other types of glaucoma, including primary angle-closure glaucoma and various forms of secondary glaucoma (e.g. secondary angle-closure, pigmentary, steroid-induced, angle-recession, neovascular, inflammatory, and pseudoexfoliation syndrome). 3. Presence of severe ocular diseases of various types that affect the acquisition of ocular parameters or interfere with perimetry. 4. Axial length \> 28 mm. 5. Monophthalmia (best-corrected visual acuity of the non-study eye \< 0.01). 6. Coexistence of severe systemic diseases affecting the entire body. 7. Pregnant or lactating women. * If both eyes of a patient meet the criteria, the eye with worse visual acuity will be selected for inclusion.
Conditions Glaucoma, OCTA, Choroid
Phase Not Applicable
Enrollment 132
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is a group of irreversible, progressive optic neuropathies that can lead to severe visual field defects and even blindness, affecting nearly 95 million people worldwide. Based on anterior chamber angle structure, glaucoma is classified into primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG). Although POAG is more common, PACG is more severe and more likely to cause blindness if not managed appropriately. Globally, PACG accounts for approximately 25% of all glaucoma cases but is responsible for roughly 50% of glaucoma-related blindness. Generally, the term "glaucoma" implies optic nerve damage; however, glaucomatous optic neuropathy may be absent in subacute and acute angle-closure glaucoma. Therefore, according to international consensus, primary angle-closure disease is categorized as PACD-encompassing primary angle-closure suspect (PACS), primary angle closure (PAC), and PACG-based on the extent of angle closure, intraocular pressure elevation, and optic nerve damage. With advances in ophthalmic imaging, an increasing array of diagnostic modalities has been applied to glaucoma diagnosis. Optical coherence tomography (OCT), which utilizes low-coherence light to display cross-sectional images of the retina in vivo, represents a rapid, non-invasive, and continuously evolving imaging method. Building upon OCT, OCTA has emerged as a novel imaging technique that allows non-invasive visualization and assessment of blood flow in individual retinal layers \[5\]. Existing OCT and OCTA research on glaucoma primarily focuses on the optic disc and macula of glaucoma patients, providing evidence of changes in the retinal nerve fiber layer, macular ganglion cell thickness, optic nerve head structure, and peripapillary and macular vasculature. Other studies have examined choroidal vascular architecture and thickness in glaucoma; previous findings from our research group also indicate that choroidal vascular density is significantly lower in eyes with POAG and PACG compared to normal eyes, while choroidal stromal area is significantly greater in PACG than in POAG eyes and normal controls. Further investigation into choroidal and retinal alterations in glaucoma is warranted. Consequently, the OCT and OCTA fundus characteristics of patients with PACD and POAG remain an area with unexplored unknowns. This study utilizes OCT and OCTA to observe the choroidal and retinal tissue structure and vascular hemodynamics in patients with PACD and POAG, aiming to comprehensively investigate structural changes in the glaucomatous fundus, broaden new research directions, and explore and supplement the understanding of glaucoma pathogenesis.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Subfoveal choroidal thickness (μm) (Day 1)
  • Deviation of the horizontal watershed zone (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-16
Completion: 2027-04-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 132 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact Information
Study Contact:
Yuheng Tan
+02066615461
tanyuhesper@163.com
Yuheng Tan
+02066615461
tanyuhesper@163.com
Zhongshan Ophthalmic Center, Sun Yat-sen University
Interventions
N/A
Study Locations (1 sites)
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060 China
Eligibility Criteria
Inclusion Criteria: * Control group: Healthy individuals with no history of ocular surgery, IOP \< 21 mmHg, and CDR \< 0.5 bilaterally without asymmetry * Observation group: Glaucoma specialist-confirmed diagnosis of POAG or PACD (per ISGEO staging: PACS/PAC/PACG) Exclusion Criteria: * History of retinal or macular disease (e.g., AMD, DR, RVO, ERM) * Non-glaucomatous optic neuropathy (e.g., MS, NMO) * Poor OCT/OCTA image quality * Refusal to sign informed consent
Conditions Open Angle Glaucoma (OAG)
Phase NA
Enrollment 165
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: VisiPlate Glaucoma Implant — Implant (micro-shunt) for glaucoma patients

Primary Outcomes

  • Proportion of subjects (eyes) achieving a ≥ 20% reduction in mean diurnal intraocular pressure (12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-07
Completion: 2027-10
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 165 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Avisi Technologies Inc.
Contact Information
Study Contact:
Katherine Lee
12816100251
kati@avisitech.com
Interventions
  • Device: VisiPlate Glaucoma Implant — Implant (micro-shunt) for glaucoma patients
Study Locations (12 sites)
Arizona Advanced Eye Research, Glendale, Arizona 85306 United States
Sacramento Eye Consultants, Sacramento, California 95815 United States
ICON Eye Care, Grand Junction, Colorado 81501 United States
Mile High Eye Institute, Sheridan, Colorado 80226 United States
Cleveland Clinic- Cole Eye Institute, Cleveland, Ohio 44195 United States
Scheie Eye Institute, Philadelphia, Pennsylvania 19104 United States
Wills Eye Hospital, Philadelphia, Pennsylvania 19107 United States
Glaucoma Associates of Texas, Dallas, Texas 75231 United States
University of Texas Southwestern, Dallas, Texas 75390 United States
The Eye Centers of Racine & Kenosha, Kenosha, Wisconsin 53142 United States
Eligibility Criteria
Inclusion Criteria: * Open angle, pseudoexfoliative or pigmentary glaucoma * IOP at preoperative visit of ≥ 20mmHg and ≤ 40mmHg * Visual field mean deviation score of -3dB or worse * Area of healthy, free and mobile conjunctiva in the target quadrant * Shaffer angle grade ≥ 2 in the target quadrant Exclusion Criteria: * Angle closure glaucoma * Congenital, neovascular or other secondary glaucomas * Previous intraocular surgery, with the exception of uncomplicated cataract surgery * Previous glaucoma shunt/valve in the target quadrant * Clinically significant inflammation or infection in the study eye within 30 days prior to the operative visit * History of corneal surgery, corneal opacities or corneal disease * Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition
Conditions Venous Leg Ulcer (VLU), Venous Hypertens...
Phase NA
Enrollment 102
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

Venous leg ulcers are a significant public health problem because of their prolonged duration, high recurrence rates, and economic, social, and quality-of-life effects. Compression therapy is the standard treatment; however, healing may remain slow. Photobiomodulation is being investigated as an adjunctive treatment to promote tissue repair and wound healing. This prospective, randomized, controlled, double-blind clinical trial will evaluate the efficacy of photobiomodulation combined with compression therapy in the healing of lower-limb venous leg ulcers. A total of 102 participants will be randomly allocated in a 1:1 ratio to an Experimental Group (n=51), receiving active photobiomodulation plus compression therapy, or a Control Group (n=51), receiving sham photobiomodulation plus compression therapy. Treatment will be administered twice weekly on Mondays and Thursdays for 16 weeks, totaling 32 sessions. The primary outcome will be the percentage reduction in wound volume over 16 weeks, estimated from wound area and depth. Secondary outcomes will include percentage reduction in wound area, change in wound depth, complete wound healing, adverse events, wound quality assessed using the Bates-Jensen Wound Assessment Tool, pain intensity and rescue analgesic use, health-related quality of life assessed using the SF-36, clinical severity assessed using the Venous Clinical Severity Score, and direct treatment costs. Wound area will be measured using the ImitoWound® application.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Photobiomodulation Therapy — The e-Light IRL cluster device (DMC Equipamentos, Brazil; ANVISA No. 80030810174) contains eight emitters: four at 660 nm and four at 808 nm. Each emitter has an output power of 100 mW and delivers 6 J over 60 seconds. Total output power is 800 mW. The applicator will be positioned perpendicular to the wound bed and applied by direct contact through disposable transparent PVC film. Appropriate protective eyewear will be used. Participants will receive active photobiomodulation twice weekly on Mondays and Thursdays for 16 weeks, totaling 32 sessions.
  • Device: Sham Photobiomodulation — This intervention uses sham photobiomodulation therapy with the same laser device as in the active group, but without emitting therapeutic laser light (inactive device). The device appears identical, and the treatment sessions are conducted twice weekly over 16 weeks, totaling 32 sessions per participant. Participants also receive standard compression therapy for the management of venous leg ulcers. This sham procedure is designed to mimic the active treatment without delivering any laser energy, serving as a placebo control.
  • Procedure: Compression Therapy — All study participants received standardized wound care and compression therapy using 30-mmHg compression stockings.

Primary Outcomes

  • Percentage Reduction in Wound Volume (Baseline, Month 1, Month 2, and Month 4)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-03
Completion: 2028-03
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Nove de Julho
Principal Investigators:
  • Anna C Ratto Tempestini Horliana, PhD (STUDY_DIRECTOR) - University of Nove de Julho
Contact Information
Study Contact:
Rayana G Moreira, MD
+5514981051703
rayanamoreira@hotmail.com
Anna C Ratto Tempestini Horliana, PhD
+5511948002288
annacrth@gmail.com
Rayana O G. Moreira, MD
+55 14 98105-1703
rayanamoreira@hotmail.com
Estratégia Saúde da Família Vereador Carlos Alberto Baptistela - Maria Cristina
Interventions
  • Device: Photobiomodulation Therapy — The e-Light IRL cluster device (DMC Equipamentos, Brazil; ANVISA No. 80030810174) contains eight emitters: four at 660 nm and four at 808 nm. Each emitter has an output power of 100 mW and delivers 6 J over 60 seconds. Total output power is 800 mW. The applicator will be positioned perpendicular to the wound bed and applied by direct contact through disposable transparent PVC film. Appropriate protective eyewear will be used. Participants will receive active photobiomodulation twice weekly on Mondays and Thursdays for 16 weeks, totaling 32 sessions.
  • Device: Sham Photobiomodulation — This intervention uses sham photobiomodulation therapy with the same laser device as in the active group, but without emitting therapeutic laser light (inactive device). The device appears identical, and the treatment sessions are conducted twice weekly over 16 weeks, totaling 32 sessions per participant. Participants also receive standard compression therapy for the management of venous leg ulcers. This sham procedure is designed to mimic the active treatment without delivering any laser energy, serving as a placebo control.
  • Procedure: Compression Therapy — All study participants received standardized wound care and compression therapy using 30-mmHg compression stockings.
Study Locations (1 sites)
Estratégia Saúde da Família Vereador Carlos Alberto Baptistela - Maria Cristina, Lençóis Paulista, São Paulo 18681-160 Brazil
Eligibility Criteria
Inclusion Criteria * Participants of either sex. * Age 19 to 85 years. * Lower-limb venous ulcer present for at least 6 weeks and not healed. * Ulcer without infection at enrollment. Operational confirmation before enrollment: * Venous etiology confirmed by Doppler ultrasonography demonstrating venous reflux. * Ankle-Brachial Index ≥0.8 to exclude concomitant arterial disease. * Written informed consent. Exclusion Criteria * Ulcer of non-venous etiology. * Pregnancy. * Severe lower-limb arterial disease. * Current use or initiation of another venous-ulcer treatment different from the study treatment. Protocol Discontinuation Criteria * Wound worsening with onset of infection. * Any complication during the procedure requiring discontinuation for participant safety.

Prognostic Model of Hypertension

NCT06160921
Recruiting
Conditions Hypertension
Phase Not Applicable
Enrollment 50000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Standard therapy — Individualized blood pressure reduction program

Primary Outcomes

  • Resistant hypertension (10 years of follow-up Resistant hypertension occurred during this period)
  • Death (all-cause mortality, mortality from hypertension complications) (10 years of follow-up deaths occurred during this period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2030-01-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 50000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xinjiang Medical University
Contact Information
Study Contact:
Xiang Xie, Phd
15099169036
xiangxie999@sina.com
Xiang xie, PHD
15099169036
xiangxie999@sina.com
The First Affiliated Hospital of Xinjiang Medicial University
Interventions
  • Other: Standard therapy — Individualized blood pressure reduction program
Study Locations (1 sites)
The First Affiliated Hospital of Xinjiang Medicial University, Ürümqi, Xinjiang 830000 China
Eligibility Criteria
Inclusion Criteria: * A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University Exclusion Criteria: * Patients with secondary hypertension, patients with liver and kidney dysfunction, * patients with mental disorders, and patients who are unwilling to participate in this trial
Conditions Hypertension
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare a multidisciplinary clinical hypertension and social needs intervention to enhanced standard of care for hypertension management in primary care clinics with regards to hypertension control outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: E3 Multidisciplinary Team — The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, and nurse working together with patients via a remote monitoring, educational hypertension phone app to overcome barriers to hypertension control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
  • Behavioral: E3 Self-Guided Hypertension Education Program — Patients will receive timed, mailed educational materials on hypertension self-monitoring, diet and lifestyle modifications to supplement usual clinic-based hypertension care with their primary care doctor. A research assistant will ensure patients have home blood pressure monitors on enrollment, and will remind patients to check their blood pressures and follow-up with their primary care doctors at 3 months and 6 months.

Primary Outcomes

  • Systolic blood pressure change at 6 months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-10
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rush University Medical Center
Collaborators: Novartis Pharmaceuticals
Principal Investigators:
  • Kristen Pallok, MD (PRINCIPAL_INVESTIGATOR) - Rush University Medical Center
Contact Information
Study Contact:
Kristen Pallok, MD
13129426700
Kristen_N_Pallok@rush.edu
Elizabeth Legorreta, MSN, NP-C
3129426700
Elizabeth_M_Legorreta@rush.edu
Kristen Pallok, MD
312-942-6700
Kristen_N_Pallok@rush.edu
Rush University Medical Center
Interventions
  • Behavioral: E3 Multidisciplinary Team — The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, and nurse working together with patients via a remote monitoring, educational hypertension phone app to overcome barriers to hypertension control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
  • Behavioral: E3 Self-Guided Hypertension Education Program — Patients will receive timed, mailed educational materials on hypertension self-monitoring, diet and lifestyle modifications to supplement usual clinic-based hypertension care with their primary care doctor. A research assistant will ensure patients have home blood pressure monitors on enrollment, and will remind patients to check their blood pressures and follow-up with their primary care doctors at 3 months and 6 months.
Study Locations (1 sites)
Rush University Medical Center, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria: * Adults 18 years or older * African American and/or Latinx * Uncontrolled stage 2 hypertension, BP \>/= 140/90 * Patient is following with Rush primary care provider in eligible Rush primary care clinics * Patient has a smart phone (Android or iOS) * Patient has an email Exclusion Criteria: * Organ transplant recipient * On dialysis * Patient is already participating in another remote hypertension monitoring program * Patient is not interested in participating in the program * Patient has already participated in the E3 Hypertension program or the E3 Diabetes program
Conditions Hypotension and Shock, Pulmonary Hyperte...
Phase PHASE4
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-29
Study Details Design, interventions, and primary outcomes

About This Study

This pilot randomized clinical trial compares dopamine and norepinephrine as first-line vasoactive therapies in term and late preterm neonates with pulmonary hypertension associated with hypoxemic respiratory failure and systemic hypotension. Systemic hypotension is a common and clinically significant complication of persistent pulmonary hypertension of the newborn (PPHN) and frequently requires vasopressor support to maintain adequate systemic perfusion. Dopamine is commonly used in this setting; however, prior animal experimental and clinical data suggest it may increase pulmonary vascular resistance, potentially worsening right ventricular afterload and hypoxemia. Norepinephrine may preferentially increase systemic vascular resistance with less effect on the pulmonary circulation. This study evaluates short-term hemodynamic and oxygenation responses following initiation of dopamine or norepinephrine.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Dopamine administration — Infants meeting the inclusion criteria who are randomized to dopamine arm will receive dopamine infusion starting at 5 mcg/kg/min, titrated to mean arterial pressure targets based on gestational age, max dose 20 mcg/kg/min.
  • Drug: Norepinephrine — Infants meeting the inclusion criteria who are randomized to norepinephrine arm will receive norepinephrine infusion starting at 0.02 mcg/kg/min, titrated to mean arterial pressure targets based on gestational age, max dose 1 mcg/kg/min.

Primary Outcomes

  • SAP/PAP ratio (Within 30 hours of vasopressor initiation.)
  • LV Cardiac output (Within 30 hours of vasopressor initiation)
  • Oxygenation Indices (Within 30 hours of vasopressor initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-10-30
Completion: 2027-06-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Davis
Collaborators: Children's Miracle Network
Principal Investigators:
  • Deepika Sankaran, MD (PRINCIPAL_INVESTIGATOR) - UC Davis Health
Contact Information
Study Contact:
Solomon P Tatagiri, MBBS
916-734-8672
solomontp@gmail.com
Solomon Tatagiri, MBBS
916-734-8672
solomontp@gmail.com
UC Davis Children's Hospital
Deepika Sankaran, MD
916-734-8672
dsankaran@health.ucdavis.edu
UC Davis Children's Hospital
Interventions
  • Drug: Dopamine administration — Infants meeting the inclusion criteria who are randomized to dopamine arm will receive dopamine infusion starting at 5 mcg/kg/min, titrated to mean arterial pressure targets based on gestational age, max dose 20 mcg/kg/min.
  • Drug: Norepinephrine — Infants meeting the inclusion criteria who are randomized to norepinephrine arm will receive norepinephrine infusion starting at 0.02 mcg/kg/min, titrated to mean arterial pressure targets based on gestational age, max dose 1 mcg/kg/min.
Study Locations (1 sites)
UC Davis Children's Hospital, Sacramento, California 95817 United States
Eligibility Criteria
Inclusion Criteria: 1. Postmenstrual age \> 34 6/7 weeks and Postnatal age ≤ 28 days 2. On respiratory support (Invasive mechanical ventilation, NIPPV, CPAP, HFNC ≥ 2 LPM) and FiO2 ≥ 0.3 3. Echocardiographic evidence of pulmonary hypertension 4. Mean arterial pressure below the threshold for gestational age despite a 10-20 mL/kg fluid bolus Permissible Comorbidities: CDH, trisomy 21, HIE on hypothermia, PDA, PFO/ASD, VSD \< 2 mm Exclusion Criteria: 1. Gestational age \< 32 weeks 2. Severe hypoxic respiratory failure (OI \> 35 or SpO2 \< 75% on 100% FiO2 for \> 60 minutes) 3. Lethal anomalies (e.g., trisomy 13 or 18) 4. Complex congenital heart disease beyond specified criteria